Experience with OK-432 in lymphatic vascular malformations in a hospital from northern Mexico Experiencia con ok-432 en malformaciones vasculares linfáticas en un hospital del norte de México uri icon


  • © 2018. Hospital Infantil de México Federico Gómez, published by Permanyer México SA de CV, all rights reserved. Background: Lymphatic vascular malformations (LVM) or formerly called lymphangiomas are congenital malformations present in about 1 out of 6,000 to 16,000 births. The most relevant classification system for lymphangioma management is based on the size of the cysts. Spontaneous resolution is uncommon; thus, expectant management is not recommended. The classic treatment is excisional surgery, but it can affect adjacent structures or have relapses, so, sclerosing substances like OK-432 are being studied. The majority of the studies are in a small sample of patients and are from Japan; the largest studies in Mexico are focused on specific lesions (macrocystic) or a determined anatomical region. To date, there are no studies of the population of the north of Mexico. Methods: The experience with OK-432 was described through a retrospective, descriptive study in patients with LVM, from 2011 to 2016, in a reference hospital of northern Mexico. Results: A total of 26 patients with LVM were treated with OK-432. The majority of the lesions were macrocystic (69%), microcystic (19%) and mixed (12%). From the total number of patients, 11 fully healed, and 72% of the study population had > 50% reduction in lesion size with only two applications. There were no recurrences. Complications were reported in two patients who had skin hyperpigmentation. Conclusions: OK-432 probed to be an effective treatment for LVM in a reference hospital in the north of Mexico.

Publication date

  • January 1, 2018